Market Overview

UPDATE: Morgan Stanley Reiterates On athenahealth Following HQ Visit

Share:
Related ATHN
Athenahealth CEO Weighs In On ACE-Chubb Merger
Healthcare IT Investors: Oppenheimer Just Made Some Waves

In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on athenahealth (NASDAQ: ATHN), but removed the $192.00 price target.

In the report, Morgan Stanley noted, “Margins [are] in focus. Management goal is to achieve annual gross margin expansion as existing products gain critical mass and new services are launched. Collector margins are already at mid-70% range, representing a proxy for gross margin expansion opportunity as product suite reaches critical mass. Adjusting for R&D and S&M growth initiatives and gross margin expansion points to long-term steady state operating margin opportunity of 30%.”

athenahealth closed on Monday at $121.07.

Latest Ratings for ATHN

DateFirmActionFromTo
Jul 2015Canaccord GenuityInitiates Coverage onHold
Jun 2015OppenheimerInitiates Coverage onOutperform
Mar 2015RW BairdInitiates Coverage onOutperform

View More Analyst Ratings for ATHN
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (ATHN)

Get Benzinga's Newsletters